<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794997</url>
  </required_header>
  <id_info>
    <org_study_id>2019P003607-13</org_study_id>
    <nct_id>NCT05794997</nct_id>
  </id_info>
  <brief_title>Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol</brief_title>
  <official_title>Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rutgers University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset&#xD;
      between patients treated with medications that target specific metabolic pathways and&#xD;
      patients treated with alternative medications for the same indication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, non-interventional study that is part of the DREAM Study of Brigham&#xD;
      and Women's Hospital. DREAM is led by Dr. Madhav Thambisetty, MD, PhD, Chief of the Clinical&#xD;
      and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National&#xD;
      Institute on Aging (NIA) intramural research program. This study aims to evaluate the&#xD;
      comparative risk of dementia/Alzheimer's disease onset between patients treated with&#xD;
      medications that target specific metabolic pathways and patients treated with alternative&#xD;
      medications for the same indication using healthcare claims data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 30, 2022</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to dementia onset</measure>
    <time_frame>From date of drug initiation until the first of dementia onset, end of Medicare enrollment, or end of study period, whichever came first, assessed up to 6 years]</time_frame>
    <description>Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Alzheimer's disease onset</measure>
    <time_frame>From date of drug initiation until the first of Alzheimer's disease onset, end of Medicare enrollment, or end of study period, whichever came first, assessed up to 6 years</time_frame>
    <description>Time to Alzheimer's disease onset. Please refer to uploaded protocol for full definition due to size limitations.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">817337</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Propranolol or Carvedilol</arm_group_label>
    <description>Exposure group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atenolol, Bisoprolol or Sotalol</arm_group_label>
    <description>Reference group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol or Carvedilol</intervention_name>
    <description>Propranolol or Carvedilol claim is used as the exposure group.</description>
    <arm_group_label>Propranolol or Carvedilol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol, Bisoprolol or Sotalol</intervention_name>
    <description>Atenolol, Bisoprolol or Sotalol claim is used as the reference group.</description>
    <arm_group_label>Atenolol, Bisoprolol or Sotalol</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will employ a new user, active comparator, observational cohort study design&#xD;
        comparing Propranolol or Carvedilol to hydrochlorothiazide. The patients will be required&#xD;
        to have continuous enrollment during the baseline period of 365 days before initiation of&#xD;
        Propranolol or Carvedilol or Atenolol, Bisoprolol or Sotalol (index date). Follow-up for&#xD;
        the outcome (dementia) differs between analyses. Follow-up begins the day after drug&#xD;
        initiation (analysis 1, 3, 4); 180 days after drug initiation (analysis 2).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Please see&#xD;
        https://drive.google.com/drive/folders/1eqhYGcjNDNnk_cKTgiKQyX3ntdD3xLnY?usp=sharing or&#xD;
        Appendix A for full code and algorithm definitions.&#xD;
&#xD;
        Medicare timeframe: 2008 to 2019 (end of data availability).&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Aged &gt;/= 65 years on the index date&#xD;
&#xD;
          -  2. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to&#xD;
             and including cohort entry date&#xD;
&#xD;
          -  3. At least 1 inpatient claim or 2 outpatient claims with hypertension diagnosis&#xD;
             recorded in 365 days prior to drug initiation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Prior history of dementia measured anytime prior to cohort entry date&#xD;
&#xD;
          -  2. Prior history of nursing home admission in the 365 days prior to the cohort entry&#xD;
             date&#xD;
&#xD;
          -  3. Prior use of Propranolol, Carvedilol and Atenolol, Bisoprolol, Sotalol&#xD;
&#xD;
          -  4. Use of Propranolol, Carvedilol and Atenolol, Bisoprolol, Sotalol concomitantly on&#xD;
             index date&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhav Thambisetty, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Aging (NIA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 3, 2023</study_first_submitted>
  <study_first_submitted_qc>March 29, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 29, 2023</last_update_submitted>
  <last_update_submitted_qc>March 29, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Rishi J. Desai</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Sotalol</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

